LOSARTAN POTASSIUM

Post-LOE

losartan potassium

Merck & Co.

ANDAORALTABLET

Approved

Sep 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

LOSARTAN POTASSIUM (losartan potassium) by Merck & Co. is [formed from angiotensin i in a reaction catalyzed by angiotensin converting enzyme (ace, kininase ii)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. Approved for hypertension in adults, older, to lower blood pressure and 9 more indications. First approved in 2012.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

[formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone…

Indications (11)

hypertension in adults

Worked on LOSARTAN POTASSIUM at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (7)

NCT03459911Phase 1Completed

A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting Conditions

Started Feb 2018

66 enrolled

Healthy

NCT03029091Phase 2Completed

An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)

Started May 2017

15 enrolled

Eosinophilic Esophagitis

NCT00856271Phase 3Completed

Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

Started Aug 2004

287 enrolled

Essential Hypertension

NCT01149473Phase 1Completed

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions

Started Mar 2004

80 enrolled

Healthy

NCT00185094Phase 4Completed

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Started Feb 2004

60 enrolled

HypertensionInsulin ResistanceMetabolic Syndrome